FDA backs Alterity Therapeutics (ATHE) ATH434 Phase 3 CMC and trial prep
Rhea-AI Filing Summary
Alterity Therapeutics Limited reports that the U.S. FDA has provided positive regulatory feedback in a second Type C Meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA). The agency and company reached alignment on key chemistry, manufacturing, and control (CMC) elements, supporting readiness for Phase 3 initiation while manufacturing scale-up progresses in parallel. An End-of-Phase 2 meeting with the FDA remains on track for mid-2026, positioning ATH434 for a pivotal trial in this rare, rapidly progressive neurodegenerative disease with no approved disease-modifying treatments.
Positive
- FDA alignment on ATH434 CMC for Phase 3: The FDA provided positive feedback and endorsed Alterity’s chemistry, manufacturing, and control plans for ATH434, reducing a key source of regulatory risk ahead of the planned pivotal Phase 3 trial in Multiple System Atrophy.
- Clear regulatory path toward pivotal trial: With two Type C Meetings completed and an End-of-Phase 2 meeting on track for mid-2026, the ATH434 program now has structured FDA interaction supporting readiness for Phase 3 initiation in a rare disease lacking disease-modifying treatments.
Negative
- None.
Insights
Positive FDA feedback de-risks ATH434’s path into Phase 3 MSA trials.
The FDA’s endorsement of ATH434 plans after a second Type C Meeting is a key regulatory milestone for Alterity Therapeutics. Alignment on chemistry, manufacturing, and control (CMC) means the company’s technical package for Phase 3 and potential commercialization has cleared an important hurdle.
Manufacturing scale-up is progressing in parallel with Phase 3 planning, which may help avoid delays once the pivotal trial is ready to start. An End-of-Phase 2 meeting targeted for mid-2026 will be crucial to finalize the overall Phase 3 design in Multiple System Atrophy, a disease with no approved disease-modifying therapies.
For investors, this update reduces regulatory uncertainty around ATH434’s development path but does not remove clinical or financing risks described in existing risk disclosures. Subsequent company reports around the End-of-Phase 2 meeting in 2026 will likely clarify the Phase 3 protocol and timelines.
Key Figures
Key Terms
Type C Meeting regulatory
chemistry, manufacturing, and control (CMC) technical
End-of-Phase 2 meeting regulatory
Multiple System Atrophy medical
disease modifying treatments medical
development stage enterprise financial
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
Alterity Receives Positive FDA Feedback on CMC Meeting |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: April 27, 2026
Exhibit 99.1
Alterity Therapeutics Receives Positive FDA Feedback Following Second
Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
– Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program –
– Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing in parallel –
– End-of-Phase 2 meeting with FDA remains on track for mid-2026 –
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 27 April 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). MSA is a rare, rapidly progressive neurodegenerative disease with no approved disease-modifying treatments.
This second Type C Meeting builds on Alterity’s recent regulatory interactions with the FDA and represents a further step towards readiness for the planned Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the chemistry, manufacturing, and control (CMC) elements of the program. The first Type C Meeting, which was announced in March, related to clinical pharmacology and non-clinical development aspects of the program.
“Confirming alignment with the FDA on the chemistry and manufacturing of ATH434 represents another critical step toward initiation of our Phase 3 program,” said David Stamler, M.D., Chief Executive Officer of Alterity. “The FDA endorsed our plans related to the manufacture and testing of ATH434 for use in our Phase 3 trial and ultimately for commercialization, if approved. We continue to advance ATH434 through the necessary steps to initiate our pivotal development program, and we look forward to finalizing our plans with the FDA at an End-of-Phase 2 meeting that remains on track for mid-year 2026.”
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorized by the Board of Alterity Therapeutics Limited.
Contacts:
Investors:
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.